Global Minimally Invasive Vertebral Compression Fracture Treatment Market to Show Moderate Growth

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, rising procedure volumes, driven by improving reimbursement and expanding demographic factors, are leading to market growth and a subsequent increase in competition in the global minimally invasive vertebral compression fracture (MIVCF) treatment market. The overall market will grow moderately to reach a total value of nearly $790 million by 2017. Clinical findings published in the New England Journal of Medicine in 2009 led to doubts among referring surgeons as well as the general public about the efficacy of vertebroplasty and, by extension, vertebral augmentation, and had a strong negative effect on the overall MIVCF treatment market. More recently, support from operating surgeons and health authorities including the Japanese government and organizations such as the North American Spine Society (NASS), have dissipated some of these negative effects. Additional positive clinical data from current studies will continue to assist in market recovery. Medtronic is currently the worldwide market leader due to its historic domination of the vertebral augmentation segment, the more lucrative of the two MIVCF segments. More recently, however, the company has faced increasing competition from new market entrants, particularly in the United States and European markets. Medtronic has compensated for its loss of market share in these markets by positioning itself for strong growth in the Asia Pacific market, where its balloon kyphoplasty device was the first vertebral augmentation device to be approved for use and reimbursement in January 2011, giving the company a considerable competitive advantage. Innovations that enhance patient outcomes and enhance ease-of-use for physicians will give competitors a significant advantage through 2017,” said MRG Analyst Mashkur Reza.For example, DFINE’s VertecoR MidLine Navigational Osteotome and CareFusion’s curved injection needle utilize unipedicular access and targeted cement placement, which are important characteristics to a fair number of users. Increasing competition has led to declines in average selling prices, which favors companies with substantial manufacturing capabilities that can benefit from economies of scale. Larger companies with broad product portfolios that include other spine and orthopedic products will also be at an advantage because they can offer bundled packages sold at a discount. Millennium Research Group Global Markets for Minimally Invasive Vertebral Compression Fracture Treatments 2013 report includes unit, installed base, average selling price and revenue information, along with market drivers and limiters and competitive landscape for vertebroplasty and vertebral augmentation in the United States, Europe (France, Germany, Italy, United Kingdom) and Asia Pacific (Australia, Japan, South Korea) markets. About Millennium Research Group Millennium Research Group , a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions. About Decision Resources Group Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions.